Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on March 17, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement). Indivior issued convertible notes (144A private placement) to qualified institutional buyers: not publicly offered.
Indivior Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Indivior issued convertible notes (144A private placement) to qualified institutional buyers: not publicly offered
- Max 16,202,200 common shares issuable upon conversion, representing meaningful potential dilution
- Initial max conversion rate of 32.4044 shares per $1,000 principal: conversion price implied ~$30.86/share
- Anti-dilution adjustment provisions apply, meaning conversion rate (and dilution) could increase over time
Item 1.02 · Termination of a Material Definitive Agreement
- Full prepayment of all outstanding principal, accrued interest, and fees under the Note Purchase Agreement on March 17, 2026
- Facility originated November 4, 2024, with Piper Sandler Finance LLC as Administrative Agent; terminated same day as prepayment
- Prepayment funded by proceeds from a separate Convertible Notes Offering, signaling a debt refinancing/restructuring event
- Note Purchase Agreement had been amended as recently as January 26, 2026, suggesting prior covenant or structural issues before replacement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Indivior Pharmaceuticals, Inc. 8-K filings
Get the next INDV 8-K as it lands
Follow INDV for push alerts, or ask the research agent what this filing means.